The curious constraints on clofazimine
Journal of Antimicrobial Chemotherapy · 2026
DOI: 10.1093/jac/dkaf430 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2026. Verfasst von Maple Goh und 2 weiteren Autor:innen. Beteiligte Einrichtung: Program On Regulation, Therapeutics And Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hosp…. Hauptthemen laut MEDLINE: Clofazimine, Leprostatic Agents, Leprosy, Multibacillary. Die Arbeit nennt 51 Literaturangaben. Gefördert von: Arnold Ventures.
Abstract (Originalsprache)
Clofazimine is a WHO-recommended therapy for multibacillary leprosy and an emerging option for drug-resistant tuberculosis and non-tuberculous mycobacterial infections. Yet in high-income countries like the USA, access remains restricted through expanded access pathways and other limitations, despite decades of safe use. This review examines clofazimine’s regulatory trajectory in the USA, contrasts global access models, and highlights the consequences of relying on a single manufacturer and informal donation programmes. We argue that existing systems can be ill-suited to ensure equitable, sustainable access to essential but low-profit medicines like clofazimine. Policy options include simplified access pathways, WHO-based procurement for leprosy, and public manufacturing to stabilize supply. Clofazimine’s case illustrates the need for proactive stewardship and access models that align with public health goals.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Program On Regulation, Therapeutics And Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital/Harvard Medical School, 1620 Tremont, Suite 3030, Boston, MA 0212…
- Boston University School of Law, CARB-X, 765 Commonwealth Avenue, Boston, MA 02215, USA.
- Tufts University School of Medicine, Department of Public Health and Community Medicine, 800 Washington St, Boston, MA 02111, USA.
ORCID-Profile: Maple Goh, Aaron S Kesselheim
Förderung
- Arnold Ventures
Zitieren
APA
Goh, M., Eisenkraft Klein, D., & Kesselheim, A. S. (2026). The curious constraints on clofazimine. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf430
Vancouver
Goh M, Eisenkraft Klein D, Kesselheim AS. The curious constraints on clofazimine. Journal of Antimicrobial Chemotherapy. 2026. doi:10.1093/jac/dkaf430
BibTeX
@article{Goh2026,
author = {Goh, Maple and Eisenkraft Klein, Daniel and Kesselheim, Aaron S},
title = {The curious constraints on clofazimine},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2026},
doi = {10.1093/jac/dkaf430}
}
EUVIMED